The Right to Leave
Who controls the next manufacturing decision, and what it costs to keep that choice.
Could you get your product manufactured somewhere else if you needed to? A termination clause answers only part of that question. This report examines the records, permissions, receiving capacity, regulatory evidence and people needed to preserve the next manufacturing decision, and the separate economics of reducing commitments when a programme changes.
Third edition, September 2026 · Research cut-off: 16 September 2026
What this report answers
- Am I protecting continuing supply, reducing future purchase commitments, or preserving a choice of independent supplier?
- What would a receiving manufacturer need to accept before our transfer right becomes usable?
- Do both manufacturing routes depend on the same owner, licence, critical material or release capability?
- What remains payable if the programme stops or the production forecast falls?
- How much additional protection would a readiness package buy beyond the rights, documents and backups we already have?
- Which executive owns the transfer decision, and who can stop it if quality or regulatory evidence is insufficient?
- Which public developments would support or contradict the report's forecasts through 2028?
26 agreements
A purposively selected public agreement corpus. Its observations describe those documents and cannot estimate how common a clause is across private or unfiled contracts.
8 forecasts
Dated calls with fixed observation rules through 2028. These are ProGen forecasts and editorial tests, not measured probabilities or established market outcomes.
What the analysis establishes
Three decisions that need different protection
Supply continuity keeps a continuing programme supplied. Commitment flexibility limits obligations when production needs change. Supplier independence preserves a usable choice outside shared ownership, permissions or critical-input dependencies. The report separates these tests before asking what an alternative route is worth.
The distance between permission and execution
Selected public manufacturing agreements show how transfer rights, assistance, delivery deadlines and IP permissions differ. The analysis follows those obligations through four interacting gates: legal rights, technical readiness, regulatory evidence and receiving capacity. A promise to cooperate is assessed separately from an accepted package and a qualified supply route.
The cost of moving, and the cost of stopping
The disclosed cases distinguish a continuing programme that moves from one that winds down, changes capacity or brings manufacturing in-house. Cash payments, accounting charges and future commitments retain their original meanings. Illustrative models then test the incremental value of readiness to a sponsor against the delivery economics of an incumbent or receiving provider.
What must travel with the programme
An ADC, an autologous cell therapy and a radiopharmaceutical do not have the same transfer object. The modality analysis examines the process, materials, analytical methods, licences and supply dependencies that must remain usable, including complex biologics, peptides and oligonucleotides. It asks which failure a second route actually protects against.
A funded operating responsibility
The proposed response stages work through Preserve, Prepare, Demonstrate, Maintain and Activate, with named decision owners, evidence gates and stop rules. Eight dated forecasts to 2028 have explicit observation tests. They remain forecasts, while the operating framework gives management a way to decide what deserves funding now.
How it was built
The analysis draws on public filings, regulatory publications, company disclosures, published research and identified third-party reporting. It includes a selected 26-agreement corpus, an openFDA letter retrieval and a job-posting snapshot, each with its own definitions and limits. Selected cases and agreements are not representative market samples. Financial calculations are illustrative decision models with replaceable assumptions; forecasts are separated from historical evidence. Sources and model definitions are included in the report.
Who it is for
Biotech and CDMO decision-makers across commercial leadership, CMC, MSAT, technical operations, manufacturing, quality and regulatory affairs. It is also written for boards and investors assessing a manufacturing dependency, a receiving-provider proposition or the leadership needed to execute a change.
What you can use
- A three-part diligence framework for continuity, commitment flexibility and supplier independence.
- Selected agreement clauses and the delivery obligations to test with an incumbent and a receiving provider.
- Illustrative sponsor and provider economics, sensitivities and model definitions for replacing the assumptions with programme evidence.
- A proposed staged governance model with accountable owners, acceptance criteria and stop rules.
- Eight dated forecasts with fixed public tests, so later evidence can change the assessment.
Contents
- I / The central finding
- II / The natural experiments
- III / The frequency of the trigger
- IV / What the contracts actually say
- V / The regulatory clock
- VI / The cost of leaving
- VII / Modality by modality
- VIII / Who is monetizing portability
- IX / The two-sided economics
- X / Trends and predictions, 2026-2028
- XI / The operating response
- Model definitions, assumptions and sources
Modalities covered
ADCs, cell and gene therapy, radiopharma, complex biologics, peptides and oligonucleotides
The full 69-page briefing is free. Tell us where to send it and it downloads immediately.
About ProGen
Byron Fitzgerald, founder of ProGen Search, connects market structure with the operating responsibilities it creates. ProGen combines retained executive search and commissioned market intelligence in complex life sciences: define the decision and its constraints, then identify the leadership accountable for delivering it.
Leadership briefs built around outcomes, interfaces and decision rights across commercial and technical functions.
Capability, competitor and supplier mapping around a defined decision, with disclosed facts and unresolved questions kept distinct.